Pneumocystis pneumonia (PCP)

Synonyms
PJP, Pneumocystis jirovecii pneumonia, pneumocystosis
Specialty
Internal medicine · Infectious diseases
Images
CT 1 · Histology 1
Last updated
10/2026 · Dr. Pascal Bafteh
Contents
  1. Images (2)
  2. Definition
  3. Occurrence & epidemiology
  4. Aetiopathogenesis
  5. Clinical features
  6. Histology
  7. Diagnosis
  8. Treatment principles
  9. Keep learning in the app
  10. Further reading (open access)
  11. Cross-references

Images (2)

Pneumocystis pneumonia (PCP) – Chest X-ray and CT in HIV infection: bilateral, diffuse ground-glass opacities predominating in the mid lung (Pneumocystis pneumonia)CT
Chest X-ray and CT in HIV infection: bilateral, diffuse ground-glass opacities predominating in the mid lung (Pneumocystis pneumonia)Image: Hellerhoff (Wikimedia Commons) · CC BY-SA 4.0 · Source
Pneumocystis pneumonia (PCP) – Histology (H&E): foamy, eosinophilic exudate in the alveoli and interstitial inflammation in Pneumocystis pneumoniaHistology
Histology (H&E): foamy, eosinophilic exudate in the alveoli and interstitial inflammation in Pneumocystis pneumoniaImage: Yale Rosen from USA, “Pneumocystis jiroveci infection (3833203709)” (Wikimedia Commons) · CC BY-SA 2.0 · Source
1 / 2

Definition

Pneumocystis pneumonia (PCP, also PJP) is a pneumonia caused by the atypical fungus Pneumocystis jirovecii (formerly P. carinii). It occurs almost exclusively with impaired cell-mediated immunity and is one of the most important opportunistic infections in advanced HIV infection; in people with HIV it is an AIDS-defining illness.

Occurrence & epidemiology

  • P. jirovecii occurs worldwide. Primary infection usually occurs in early childhood; most immunocompetent children have developed specific antibodies by the age of 4 years.
  • Since effective HIV medicines became available, the frequency among people with HIV has fallen sharply in well-resourced countries. A high risk persists in undiagnosed HIV infection, especially with CD4 counts below 200/µL or below 14 % (HIV stage 3).

Aetiopathogenesis

  • Pathogen: Pneumocystis jirovecii, originally classified as a protozoon, has been considered a fungus since the 1990s based on molecular analyses. Its life cycle consists of trophic forms and cysts.
  • Transmission: airborne; causes no disease in immunocompetent people.
  • Risk groups: HIV infection with a low CD4 count; organ transplant recipients; hematologic cancers; use of immunosuppressive drugs.

Clinical features

  • Leading symptoms: fever, dyspnea (initially on exertion) and dry, nonproductive cough; occasionally chest discomfort.
  • Course: insidious over several weeks in HIV infection, faster over a few days in other forms of immunodeficiency.
  • Findings: tachypnea and tachycardia, especially on exertion; on auscultation sometimes diffuse fine crackles, but often normal.
  • Hypoxemia as the hallmark finding, often with oxygen desaturation on exertion.
  • Complications: spontaneous pneumothorax, respiratory failure.

Histology

In tissue, bronchoalveolar lavage or induced sputum, the organizms are found in the alveolar spaces. Giemsa, Diff-Quik and Wright stains show trophic forms and cysts without staining the cyst wall; Grocott-Gomori methenamine silver (GMS), Gram-Weigert, cresyl violet and toluidine blue stains specifically mark the cyst wall. Most stains have low sensitivity; some laboratories additionally use direct immunofluorescence with monoclonal antibodies.

Diagnosis

  • Chest X-ray: typically bilateral, diffuse perihilar or fine granular opacities; in 20–30 % the radiograph is normal.
  • Chest CT: ground-glass opacities, even with a normal radiograph; a normal CT makes PCP very unlikely.
  • Pulse oximetry and arterial blood gas analysis: hypoxemia and increased alveolar-arterial oxygen gradient, sometimes before infiltrates are visible.
  • Laboratory tests: elevated serum 1,3-beta-D-glucan and LDH support the suspicion but are nonspecific.
  • Pulmonary function testing: reduced diffusing capacity (rarely used for diagnosis).
  • Pathogen detection: from induced sputum, bronchoalveolar lavage or tracheal aspirate; bronchoalveolar lavage is considerably more sensitive than induced sputum. Nucleic acid amplification (PCR) is considered the gold standard with the highest yield; in addition immunofluorescence and microscopic stains.
  • HIV test in every case of PCP without a known cause of immunodeficiency.

Treatment principles

  • Treatment is antimicrobial therapy active against Pneumocystis, with alternative agents in case of intolerance.
  • In significant hypoxaemia, adjunctive glucocorticoids are given; oxygen and ventilatory support as needed complement treatment.
  • In HIV infection, antiretroviral therapy is started promptly; patients with significant immunosuppression then receive secondary prophylaxis.

Specific treatment regimens with drugs and doses are covered in the InnereFuchs app.

Keep learning in the app

In the InnereFuchs app you can learn Pneumocystis pneumonia (PCP) with flashcards, exam questions and image tasks (ECG, chest X-ray, ultrasound, lab values) – free, in your browser or as an app.

Open in browser  About InnereFuchs →

Further reading (open access)

  1. MSD Manual Professional: Pneumocystis jirovecii Pneumonia
  2. RKI-Ratgeber: HIV-Infektion/AIDS

Cross-references

Keep learning

Keep learning with flashcards, exam questions and spot diagnoses in the InnereFuchs app – free, in your browser or as an app.

Related pages: Sepsis and septic shock · HIV infection and AIDS · Influenza (flu)

Note: Learning content for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.